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HEMATOPOIESIS
Cessation of intensive treatment with recombinant human erythropoietin is
followed by secondary anemia
Maude Piron, Martine Loo, Andre´ Gothot, Franc¸oise Tassin, Georges Fillet, and Yves Beguin
Little information is available on the
evolution of erythropoiesis after inter-
ruption of recombinant human erythro-
poietin (rHuEpo) therapy. Iron-over-
loaded rats received 20 daily injections
of rHuEpo. During treatment, reticulo-
cytes, soluble transferrin receptor
(sTfR), and hematocrit increased pro-
gressively. This was accompanied by a
substantial expansion of spleen erythro-
poiesis but a decrease in the bone mar-
row. Five weeks after treatment, rats
developed a significant degree of ar-
egenerative anemia. Erythropoietic ac-
tivity, as assessed by reticulocytes,
sTfR, erythroid cellularity, iron incorpo-
ration into heme, and the number of
erythroid colonies, was severely de-
pressed 3 weeks after cessation of
rHuEpo. This was followed by regenera-
tion of erythroblasts and reticulocytes
at weeks 6 to 7 post-Epo, but erythroid
progenitors recovered only partially by
that time. The anemia was definitely
corrected 2 months after cessation of
rHuEpo treatment. Serum Epo levels
remained elevated for several weeks,
but the sensitivity of marrow erythroid
precursors to Epo was preserved. No
rat antibodies to rHuEpo were detected,
and serum from post-Epo animals did
not exert any inhibitory activity on eryth-
ropoiesis. In conclusion, after cessa-
tion of intensive rHuEpo therapy, there
was a strong inhibition of erythropoi-
etic activity with secondary anemia fol-
lowed by late recovery. This was not
due to antibodies or other soluble in-
hibitory factors, a defect in endogenous
Epo production, or a loss of sensitivity
to Epo. This may rather represent in-
trinsic erythroid marrow exhaustion,
mostly at the level of erythroid pro-
genitors but also at later stages of
erythropoiesis. (Blood. 2001;97:442-448)
© 2001 by The American Society of Hematology
Introduction
Recombinant human erythropoietin (rHuEpo) has been used
extensively to treat the anemia of renal failure and is increas-
ingly considered for use in other situations.1 In normal subjects,
rHuEpo elicited a dose-dependent stimulation of erythropoiesis,
resulting in elevated reticulocytes, soluble transferrin receptors
(sTfRs), and hematocrit (Hct),2-5 allowing for the collection of
multiple red blood cell units.6,7 The magnitude of the erythropoi-
etic response was similar in normal subjects, in patients with
genetic hemochromatosis, and in patients with the anemia of
chronic renal failure.8 After cessation of treatment, one would
expect a gradual return of all erythroid parameters to baseline
levels. This has never been studied in normal subjects, except in
the setting of surgery and/or autologous blood donation. How-
ever, it is obvious that inflammation, bleeding, and transfusions
associated with surgery, as well as anemia and iron deficiency
associated with phlebotomy will preclude any meaningful
interpretation of posttreatment changes in terms of overall
erythroid marrow capacity to produce red cells. Therefore, we
designed a study in normal rats to examine the long-term
evolution of erythropoiesis after stopping intensive treatment
with rHuEpo. Surprisingly, we did not simply observe a gradual
return to baseline, but rather a diphasic evolution of profound
inhibition of erythropoiesis and anemia before appropriate
marrow response to correct this anemia.
Material and methods
Animals and rHuEpo therapy
Male Wistar rats were obtained from Janssen (Beerse, Belgium) and raised
at the University of Lie`ge from the age of 3 weeks through the end of the
experiment. They were fed standard food in powder form supplemented
with 1% (wt/wt) carbonyl iron (Sigma Chemical, St Louis, MO) 6 days per
week and normal granular food 1 day per week. Rats were aged 3.5 to 4
months at the time of the experiments. Some animals underwent splenec-
tomy under general anesthesia with ether (Gifer Barbezat, Dicenes, France)
followed by placement of autoclip mikron clips (Becton Dickinson
Benelux, Erembodegem-Alst, Belgium) for 10 days. They were then left to
stabilize for 30 days before the experiment, and only animals showing no
sign of inflammation at that time were used. Other rats underwent the same
procedure but without splenectomy (sham-operated). To examine the effect
of polycythemia per se (without any exposure to rHuEpo), a group of 4 rats
were transfused with 5 mL packed red cells for 3 consecutive days and then
2 mL every other day for 32 days so as to maintain their Hct around 65%.
Donor animals were pretreated with 35 mg thiamphenicol daily for 4 days,
and donor blood was washed thrice with saline to provide reticulocyte- and
plasma-free red cells.
rHuEpo (Recormon) was kindly provided by Boehringer-Mannheim
(Brussels, Belgium). Rats were injected daily with intravenous rHuEpo at a
dose of 150 U/d for 20 days. Control animals received the same volume of
normal saline. Blood samples were drawn from a tail vein under short ether
anesthesia 3 times per week just before rHuEpo injections. Part of the blood
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was drawn on ACD formula A and part on heparin to be centrifuged to
obtain plasma, which was frozen at 220°C until processing.
Serum preparation
Blood was collected by aortic puncture from control untreated animals as
well as day 15 post-Epo animals and centrifuged 10 minutes at 400g. The
serum was further centrifuged at 5000g for 20 minutes to eliminate
platelets, sterilized by filtration through a 0.22-mm Millipore filter, and
stored at 220°C. It was tested at 10% concentration in assays of
hematopoietic progenitors and of iron incorporation into heme (see below).
Cell suspensions
Single cell suspensions were obtained from bone marrows (femur) and
spleens of rats killed 0, 20, or 40 days after cessation of treatment with
rHuEpo or control untreated rats. They were prepared in Iscove modified
Dulbecco medium (IMDM; Bio-Whittaker Europe, Verviers, Belgium)
containing 1% fetal bovine serum (Myoclone, Bio-Whittaker Europe). The
bone marrow was flushed and aspirated through a 23-gauge and then a
25-gauge needle, and the spleen was crushed. Cell suspensions were then
filtered through a nylon mesh to remove aggregates. Cells were counted in a
Technicon H2 automatic cell counter, and total marrow or spleen cellularity
was calculated. The proportions of erythroid and granulocytic lineage cells
in the bone marrow and spleen were obtained by counting 200 cells after
staining with May-Gru¨mwald-Giemsa.
Progenitor assays
Spleen and marrow cell suspensions were treated with a NH4Cl solution
(0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2 EDTA; pH 7.2-7.4) to lyse red
blood cells. Colony-forming unit–erythrocyte (CFU-E), burst-forming unit,
erythroid (BFU-E), colony-forming unit–granulocyte-macrophage
(CFU-GM), and CFU-Mix were estimated in semisolid serum-free IMDM
culture medium containing 0.9% methylcellulose (StemCell, Vancouver,
Canada), 1% bovine serum albumin (BSA), 10 mg/mL bovine pancreatic
insulin (StemCell), 200 mg/mL human iron-saturated transferrin (Stem-
Cell), 0.1 mM b-mercaptoethanol (Sigma Chemical), 2 mM L-glutamine
(Life Technologies, Paisley, United Kingdom), 100 U/mL penicillin (Life
Technologies), 10 mg/mL streptomycin (Life Technologies), 10 ng/mL
recombinant murine interleukin 3 (IL-3; PeproTech, Northampton, United
Kingdom), 10 ng/mL recombinant human IL-6 (Novartis, Basel, Switzer-
land), 50 ng/mL recombinant murine stem cell factor (PeproTech), and 2
U/mL rHuEpo (Boerhinger Mannheim). Either 3 or 4 rats were used for
each condition, and assays were run in duplicates. Cells were incubated at
37°C in a humidified 5% CO2 atmosphere at a concentration of 1.5 3 105/
mL (bone marrow) or 3 3 105/mL (spleen). CFU-Es were scored after 7
days and BFU-E, CFU-GM, and CFU-Mix after 14 days. The total number
of progenitors in the femur and in the spleen were derived, and the total
body count of each type of progenitor was calculated according to the
following equation: (progenitor count in one femur 3 13) 1 progenitor
count in the spleen.
Incorporation of iron into heme
We used the method described by Krystal et al9 with slight modifications.
Marrow cells (2 3 106/mL) were incubated 24 hours at 37°C in serum-free
IMDM containing 1% BSA, 10 mg/mL bovine pancreatic insulin, 200
mg/mL human iron-saturated transferrin, 0.1 mM b-mercaptoethanol, 2
mM L-glutamine, 100 U/mL penicillin, 10 mg/mL streptomycin, and 1%
cholesterol-rich lipids (Sigma Chemical). Epo was added at various
concentrations (0, 10, 25, 50, 100, 200, and 500 mU/mL), with each
condition done in triplicate. Cells were washed twice in warm IMDM
containing penicillin and streptomycin and centrifuged at 200g for 5
minutes at 25°C. The pellet was resuspended in 0.5 mL IMDM containing
50 mg/mL iron-free apotransferrin preincubated 1 hour at 37°C with 1
mCi/mL 59Fe citrate (specific activity 10-60 mCi/mg iron; CIS Bio
International, Gif-sur-Yvette, France). After incubating 3 hours at 37°C,
cells were washed twice in RPMI 1640 (Bio-Whittaker). Heme was
extracted by the butane-2-one method, as previously described.9 After
transfer of 1.5 mL final supernatant and 20 mL aqueous scintillation liquid
(Insta-gel plus, Packard Bioscience, Groningen, The Netherlands) to a
scintillation vial, radioactivity was counted in a b-counter (Tri-Carb
1900TR, Packard, Brussels, Belgium). 59Fe incorporation into heme was
expressed as counts per minute per 2 3 106 cells.
Miscellaneous laboratory analyses
Complete blood counts were measured on a Technicon H2 automatic cell
counter (Tarrytown, New York, NY) with appropriate corrections for
dilution by ACD. The percentage of reticulocytes was determined on a
FACSCAN cytofluorometer (Becton Dickinson, San Jose, CA) after
coloration with thiazole orange.10 Preliminary experiments showed that this
automated method gave results similar to manual counting on blood smears
colored with brilliant cresyl blue. Absolute reticulocyte counts were
calculated. Plasma erythropoietin was measured by a commercially avail-
able radioimmunoassay (Incstar Corporation, Stillwater, MN). Plasma sTfR
was measured as previously described with minor modifications.11,12 The
presence of rat antibodies to rHuEpo in rat serum was assayed by M. Kelley
(R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ), using a
validated in-house enzyme-linked immunosorbent assay.
Statistical methods
All results of in vivo experiments were calculated as percentages of a
baseline value and expressed as mean 6 standard deviation (M 6 SD).
Comparisons of baseline values with later measurements in the same
animals were carried out by paired Student t tests. Comparisons between
groups of animals were carried out with Student t tests, with the Welsch
correction in case of unequal variances. Most statistical analyses were
carried out with the Excel 5.0 (Microsoft Corp, Redmond, WA) or Prism 2.0
(GraphPad Software Inc, San Diego, CA) software packages.
Results
Figure 1 shows the evolution of erythroid parameters during
treatment of iron-overloaded rats with 150 U rHuEpo per day for
20 days. There was a progressive increase in Hct up to day 16 of
therapy, when a plateau at 160% of baseline was achieved (top
panel). The reticulocyte response was very brisk, and the maximum
increase was achieved after 8 days, when reticulocytes stabilized
around 700% of baseline values (middle panel). There was a
gradual expansion of erythropoietic activity (as measured by sTfR)
with a maximum reached also after 8 days of treatment before
stabilizing thereafter (bottom panel). The erythropoietic response
of operated rats was a little delayed but of similar magnitude.
Treatment with rHuEpo was stopped after 20 days, and rats
were followed up for 80 days following cessation of therapy
(Figure 2). There was first a gradual return of Hct to normal values
over 3 to 4 weeks (Figure 2, top panel). However, this was followed
by a continued decrease to anemic values with a nadir at 80% of
baseline values reached between day 35 and day 40 posttreatment.
Thereafter, the Hct recovered slowly over a period of about 1
month to finally stabilize at a normal level. This evolution was
identical in the 3 groups of animals.
After stopping rHuEpo, there was a very rapid drop in
reticulocyte counts that reached normal values about 10 days later
in unmanipulated or sham-operated animals (Figure 2, middle
panel). However, this drop went on to reach a nadir of about 50% of
normal values around day 20 posttreatment. The evolution in
splenectomized rats showed the same initial drop in reticulocyte
counts but without the decrease below normal levels. After
reaching their nadir, in all 3 groups of animals reticulocytes
underwent a secondary elevation up to 250% of normal values
during several weeks before returning to baseline values.
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There was a similar diphasic evolution for sTfR levels (Figure
2, bottom panel). Their initial drop was very similar to the one
observed with reticulocytes, reaching a nadir at 60% of normal
values around day 20, before undergoing a secondary expansion up
to 180% of normal erythropoietic activity. This was also followed
by a final return to normal levels.
Granulocytes and monocytes were not significantly affected by
rHuEpo therapy. We have recently reported the occurrence of
thrombocytopenia during treatment with rHuEpo and its progres-
sive return to normal values after erythropoietin withdrawal.13
Plasma Epo levels were assayed on pools of plasma obtained
within a period of 2 to 3 days in animals of the same group (Figure
3). After the last injection of rHuEpo there was a very slow
decrease of Epo values in all categories of animals. However,
normal Epo levels were only achieved by day 35, after which they
remained within appropriate limits for the Hct. The presence of rat
antibodies to rHuEpo was assayed in serum of groups of 4 rats
killed 0, 20, or 40 days after cessation of treatment with high doses
of rHuEpo as well as in control untreated animals. None of the
samples was positive.
Figure 4 describes the simultaneous evolution of the Hct,
reticulocyte count, sTfR levels, and Epo levels in unmanipulated
animals observed for almost 3 months following cessation of
rHuEpo therapy. This clearly shows a rapid decrease of erythropoi-
etic activity while the Hct progressively returned to normal and
Figure 2. Erythroid parameters after cessation of erythropoietin therapy.
Evolution of erythroid parameters in unmanipulated (closed symbols, continuous
line), sham-operated (open symbols, broken line), or splenectomized (open symbols,
continuous line) iron-overloaded rats after cessation of treatment with 150 U rHuEpo
per day for 20 days. Results are expressed as percentages of the mean value
obtained between days 70 and 80.
Figure 1. Erythropoietic response to erythropoietin. Evolution of erythroid
parameters during treatment of unmanipulated (closed symbols, continuous line),
sham-operated (open symbols, broken line), or splenectomized (open symbols,
continuous line) iron-overloaded rats during treatment with daily doses of 150 U
rHuEpo. Results are expressed as percentages of baseline value.
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endogenous Epo levels remained elevated. Despite adequate Epo
stimulation, there was a secondary anemia due to erythroid marrow
failure. This was followed by a reexpansion of erythropoiesis,
allowing for a progressive correction of the anemia. Finally, all
parameters stabilized in the normal range.
To evaluate the effect of polycythemia per se without any
exposure to rHuEpo, rats were hypertransfused for 35 days and
observed for a further 30 days (Figure 5). Polycythemia resulted in
diminished plasma Epo levels followed by severely depressed
erythropoietic activity. After cessation of the hypertransfusion
program, the return to normal Hct values was accompanied by
recovery of normal plasma Epo levels and erythropoietic activity.
Figure 6 shows the evolution of marrow, spleen, and total-body
erythroid lineage colonies (CFU-E 1 BFU-E) after cessation of
treatment with high doses of rHuEpo in iron-overloaded rats.
Compared to controls, the number of marrow erythroid colonies
decreased by 50% at the end of treatment (P 5 .004) and then
slowly recovered to 58% of control values by day 20 (P 5 .05) and
70% by day 40 (P 5 .1) posttreatment. Erythroid colonies in the
spleen increased dramatically at the end of rHuEpo therapy (5
times control values, P 5 .0008) but later decreased to 23% of
control values by day 20 (P 5 .03) and 71% by day 40 (P 5 .06)
posttreatment. As a result, total-body erythroid colonies decreased
at the end of rHuEpo treatment (77% of control values, P 5 .04),
had their nadir on day 20 posttreatment (58% of control values,
P 5 .04), and then recovered partially by day 40 (71% of control
values, P 5 .1)
A similar pattern, with minor differences, was observed for
CFU-GM (Figure 7). The nadir of marrow CFU-GM was on day 20
posttreatment (23% of control values, P 5 .04) rather than on day 0
(44% of control value, P 5 .02). The evolution of spleen CFU-GM
was similar to that of spleen erythroid colonies, although the
absolute number of CFU-GM was much lower at each time point.
The kinetics of changes in total-body CFU-GM was therefore very
similar to that observed with erythroid colonies.
The evolution of marrow and spleen cellularity correlated with
changes in progenitor numbers at the end of rHuEpo treatment
(Figure 8). Indeed, marrow cellularity decreased to 45% (P 5 .008),
and spleen cellularity increased to 350% (P 5 .0001) of control
values. The red pulp was expanded, with numerous normoblasts
and absent iron stores. Marrow erythroid cellularity (Figure 9A)
decreased to 26% of control values on day 20 posttreatment
(P 5 .0005) before increasing again to 215% on day 40 (P 5 .001).
The number of spleen normoblasts remained low at day 20 but
increased again above normal at day 40 post-Epo, with iron stores
restored to normal levels. Total marrow cellularity normalized by
day 40 and total spleen cellularity by day 20 posttreatment.
To study the evolution of marrow erythroblasts, the incorpo-
ration of iron into heme was also examined in rats killed after
treatment with rHuEpo as well as in control untreated rats. Iron
incorporation into heme (Figure 9B) paralleled the evolution of
Figure 3. Plasma Epo levels after cessation of erythropoietin therapy. Plasma
Epo values in unmanipulated (black squares) or splenectomized (white squares)
iron-overloaded rats after cessation of treatment with 150 U rHuEpo per day for 20
days. Results are expressed as percentages of the mean value obtained between
days 70 and 80. Mean 6 SD values of control untreated rats are given at the right of
the figure.
Figure 4. In vivo erythropoiesis after cessation of erythropoietin therapy.
Simultaneous evolution of the hematocrit (closed diamonds, right scale), absolute
reticulocyte count (open circles, left scale), sTfR (open triangles, left scale), and Epo
(closed squares, left scale) in unmanipulated iron-overloaded rats after cessation of
treatment with 150 U rHuEpo per day for 20 days. Results are expressed as
percentages of the mean values measured on days 70 to 80.
Figure 5. In vivo erythropoiesis during and after a program of hypertransfusion
without rHuEpo. Simultaneous evolution of the hematocrit (closed diamonds),
absolute reticulocyte count (open circles), sTfR (open triangles), and Epo (closed
squares) in rats made polycythemic by hypertransfusion for 35 days and then
observed for a further 30 days after cessation of the transfusion program. Results are
expressed as percentages of the mean baseline values.
Figure 6. Erythroid colonies after cessation of erythropoietin therapy. Evolution
of marrow (black bars), spleen (white bars), and total body (hatched bars) erythroid
lineage (CFU-E plus BFU-E) colonies 0, 20, and 40 days after cessation of treatment
with high doses of rHuEpo, compared to control untreated animals.
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erythroid cellularity: It reached its nadir (20% of control values,
P 5 .003) on day 20, before increasing to 245% of control
values on day 40 (P 5 .005). We also examined the sensitivity
of marrow erythroid precursors to Epo by measuring iron
incorporation into heme in the presence of increasing concentra-
tions of Epo, in relation to its value when no Epo is added to the
medium (Figure 10). The evolution of relative erythroblast
sensitivity to Epo was inversely correlated with absolute
changes in heme incorporation: Sensitivity to Epo was highest
on day 20 posttreatment and was lower on day 40. It thus
appeared that the poorer the bone marrow was in erythroblasts,
the more they were sensitive to Epo.
To test whether the inhibition of erythropoietic activity
observed after cessation of rHuEpo therapy was mediated by
serum factors, serum from day 15 post-Epo or from control
untreated animals was added to standard culture medium
containing 0, 10, 30, 100, or 1000 mU/mL Epo in progenitor
assays as well as in experiments of 59Fe incorporation into
heme. There was no difference in the growth of erythroid
colonies or in iron incorporation into heme between control and
post-Epo serum.
Figure 7. CFU-GM after cessation of erythropoietin therapy. Evolution of marrow
(A), spleen (B), and total body (C) CFU-GM 0, 20, and 40 days after cessation of
treatment with high doses of rHuEpo, compared to control untreated animals.
Figure 8. Marrow and spleen cellularity after cessation of erythropoietin
therapy. Evolution of marrow (black bars), spleen (white bars), and marrow plus
spleen (hatched bars) cellularity 0, 20, and 40 days after cessation of treatment with
high doses of rHuEpo, compared to control untreated animals.
Figure 9. Erythroid precursors after cessation of erythropoietin therapy.
Marrow cells were obtained 0, 20, and 40 days after cessation of treatment with high
doses of rHuEpo as well as from control untreated animals. (A) Erythroid cellularity.
(B) 59Fe incorporation into heme of erythroid precursors cultured for 24 hours in
serum-free medium without erythropoietin.
Figure 10. Sensitivity of erythroid precursors to Epo after cessation of
erythropoietin therapy. Sensitivity of marrow erythroid precursors to increasing
erythropoietin concentrations in rats sacrificed 0 (white bars), 20 (hatched bars, large
bands), or 40 (hatched bars, small bands) days after cessation of treatment with high
doses of rHuEpo, compared to control untreated animals (black bars).
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Discussion
Our study in normal rats showed that the dose of rHuEpo given was
capable of achieving a brisk erythroid response, as assessed by
substantial increases in soluble transferrin receptors and reticulo-
cytes, resulting in hematocrits above 60% after 2 weeks of
treatment (Figure 1). Changes in erythropoietic activity were of
similar magnitude but a little delayed in operated animals, probably
because of some persistent chronic inflammation after surgery.
After cessation of treatment, we first observed the expected
decrease of erythropoietic activity that led to a normalization of the
hematocrit over 25 days. However, this was followed by a
significant degree of anemia from which it took several weeks to
recover. The anemia was caused by a transient defect in the
capacity to produce red cells, as illustrated by the severe reduction
in reticulocytes and sTfR levels that preceded it. Thereafter, the
erythroid compartment regained its capacity to respond to an
appropriate erythropoietin stimulation by increasing red cell produc-
tion and correcting the anemia.
Short-term follow-up after 114 or 44 doses of rHuEpo adminis-
tered to normal volunteers showed that reticulocytes returned to
baseline and hematocrits remained stable after 7 and 14 days,
respectively. Longer but partial follow-up after cessation of rHuEpo
therapy is only available in 2 studies. In the first study, premature
infants receiving rHuEpo (300 or 750 U/kg/wk) or placebo for 6
weeks were then followed up at 2, 4, and 6 weeks after cessation of
rHuEpo and showed no sign of reticulocytopenia or anemia.15 In
the second study, normal adult monkeys receiving rHuEpo at the
dose of 100 to 250 U/kg given twice weekly for 3 weeks16 had only
a modest elevation of hemoglobin, surprisingly without reticulocy-
tosis. Available data at 3, 6, and 10 weeks posttreatment showed no
anemia, but significant reticulocytopenia was evidenced at week 3.
However, control animals receiving placebo showed the same
pattern of progressive reticulocytopenia during treatment and were
the only ones in which this remained significant at week 10
posttreatment. These results are very difficult to interpret and
cannot be compared with our data, which were also obtained with
larger doses of rHuEpo. To avoid the pitfalls of functional iron
deficiency,17 our rats were iron overloaded for 3 months before as
well as during rHuEpo therapy.
The transient suppression of erythropoietic activity we observed
may be due to inappropriate stimulation by erythropoietin or
intrinsic failure of erythroid cells to respond to that stimulus. Our
data show that erythropoietin levels were never diminished during
the course of the study but remained elevated for an unexpectedly
long period of time. These inappropriately high Epo levels could be
due to changes in Epo production rates or in Epo clearance and
utilization. It has been observed that, for similar degrees of anemia,
patients with aplastic erythroid marrow had higher serum Epo
levels than patients with iron deficiency anemia, and even more so
compared to patients with megaloblastic anemia or thalassemia
intermedia.18-20 It has also been shown that serum Epo levels
decreased rapidly on introduction of iron or vitamin B12 for the
treatment of iron deficiency20 or megaloblastic anemia20,21 well
before any detectable change in hemoglobin. Similarly, we have
observed that the kinetics of change of serum Epo levels after
autologous hematopoietic stem cell transplantation was clearly
dependent on the speed of erythroid engraftment.22 The abnormal
persistence of elevated plasma Epo levels in our study could thus
relate to suppression of erythroid activity. However, this was
contradicted by our experiment with hypertransfused rats, in which
polycythemia resulted in appropriate reduction rather than eleva-
tion of serum Epo levels, with subsequent depression of erythropoi-
etic activity. Therefore, it is unlikely that persisting elevated Epo
levels were due to nonutilization by a severely depressed erythroid
marrow. Alternatively, Bozzini et al23 have suggested the existence
of a yet unidentified feedback mechanism between Epo-responsive
erythroid cells and Epo-producing cells. Cobalt- or hypoxia-
induced Epo production in normocythemic mice is increased when
erythropoiesis is acutely depressed and reduced when erythropoi-
esis is recently stimulated.23-25 However, hypoxia-induced Epo
response in transfused polycythemic mice is much higher when
erythropoiesis has been previously stimulated for prolonged peri-
ods of time.23,25 These apparently contradictory observations in
normal and polycythemic mice may be reconciled if it is a
retracting erythron that can induce this Epo-hypersecretory state.23
However, although the erythron must shrink more after rHuEpo-
induced than after transfusion-induced polycythemia, it is unclear
how hypoxia-induced Epo production would be relevant to our
observed discrepancy in serum Epo levels between the 2 condi-
tions. Finally, even if Epo production and Epo utilization by
erythroid cells are not altered after cessation of rHuEpo therapy,
changes in Epo clearance rate could provide a valid explanation. In
normal human subjects14,26 as well as in rats,27 the initial clearance
of rHuEpo was decreased when the doses injected were increased,
approaching a plateau at high doses. In addition, the kinetics of its
final elimination has not been determined. It would thus not be
surprising that animals saturated with very high doses of rHuEpo
for 20 days would eliminate the hormone slowly from their bodies
with a long trail. Alternatively, antibodies could be generated by
repeated injections of foreign proteins and prevent the normal
clearance of rHuEpo. However, we found no direct or indirect
evidence of such rat antibodies against human erythropoietin.
Despite this more than adequate erythropoietin stimulation,
erythropoietic activity was so much suppressed as to cause anemia.
We examined a series of potential explanations. A recent report of 2
horses developing severe anemia after treatment with rHuEpo
demonstrated direct inhibition of the growth of erythroid progeni-
tors by their serum.28 Therefore, we tested the effects of serum from
post-Epo animals on the growth of BFU-E and CFU-E and on iron
incorporation into heme and found no evidence of an inhibitory
activity on erythroid precursor or progenitor cells. In addition, no
rat antibodies to rHuEpo were detected at any time during the
experiments. Furthermore, experiments of iron incorporation into
heme at various Epo concentrations (Figure 10) demonstrated that
the sensitivity of erythroid precursors to Epo was entirely pre-
served. These observations exclude that erythroid suppression was
mediated either by anti-rHuEpo antibodies or other soluble factors
or by a reduction of receptor number or affinity for Epo.
It thus appeared that erythropoietic activity could be decreased
because of an intrinsic marrow defect. This is unlikely to result from
excessive apoptosis because relatively low Epo levels are sufficient to
prevent apoptosis in CFU-E and early erythroblasts.29 Detailed analysis
of all cell categories involved in erythropoiesis indicated that the whole
process was significantly depressed around 3 weeks after cessation of
rHuEpo therapy. This was illustrated by decreased reticulocytes and
sTfR (a quantitative marker of the mass of erythroblasts), reduced
erythroid cellularity in the bone marrow and spleen, diminished iron
incorporation into heme, and smaller numbers of BFU-E and CFU-E.
Recovery of late erythropoiesis occurred within 3 additional weeks, but
full normalization of erythroid progenitors took longer. All this suggests
some form of exhaustion of erythropoiesis after intensive stimulation.
Platelet and white blood cell counts were not similarly altered, but
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CFU-GM numbers paralleled those of erythroid progenitors. Therefore,
these phenomena probably already involve an early progenitor, although
erythroid progenitors and their progeny are predominantly affected.
Fortunately, this inhibition of erythropoietic activity is only transient and
is followed by an adequate marrow response to the anemia, restoring a
normal capacity of the erythroid marrow to produce red cells.
Other observations also point toward a limited capacity of the bone
marrow to sustain intense stimulation of one cell lineage. Reciprocal
inhibition of murine erythropoiesis and granulopoiesis has been de-
scribed in splenectomized mice treated with G-CSF or rHuEpo,
respectively.30 In particular, marrow erythropoietic activity can be
severely depressed after G-CSF treatment, resulting in anemia.30,31
However, this has not yet been reproduced by other groups. Similarly,
moderate doses of rHuEpo may cause an elevation of platelet counts,32,33
but large chronic doses induce thrombocytopenia,34 particularly in
iron-replete animals,13 suggesting competition between the 2 cell
lineages at the level of a common precursor.35,36 This has been well
documented in a number of other studies.37
These observations of possible competition between different cell
lineages as well as those of potential exhaustion after intensive
stimulation indicate that caution should be applied before implementing
high-dose therapy with multiple hematopoietic growth factors. Fortu-
nately, moderate doses of rHuEpo in subjects with intact erythroid
marrow do not appear to produce a secondary anemia after cessation of
therapy.15 However, although our observations were obtained with very
large doses of rHuEpo, lower doses may exert similar effects in
situations of limited residual hematopoiesis, such as after multiple
courses of chemotherapy or after hematopoietic stem cell transplanta-
tion. Such studies are ongoing in our laboratory. Whereas rHuEpo could
accelerate erythroid recovery and reduce the need for transfusions in
these situations, there might be a risk for more anemia after high-dose
erythropoietin is stopped. If this were the case, progressive reduction of
rHuEpo dosage rather than abrupt withdrawal would allow avoiding
such secondary anemia.
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